{"doi":"10.1016/j.gore.2020.100554","title":"Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma","abstract":"BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. CASE: We describe two USC patients with overexpression of HER2/neu at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplification by fluorescence in situ hybridization (FISH) assay that, after an initial clinical response to trastuzumab, developed resistance/progression. Post-treatment biopsy (collected at the time of clinical progression on trastuzumab) demonstrated loss of HER2/neu overexpression in the recurrent/progressing tumor cells in both patients. CONCLUSION: Selection of HER2/NEU negative tumor cells may represent a major mechanism of resistance to trastuzumab in USC patients.","journal":"Gynecologic Oncology Reports","year":2020,"id":109682,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.956,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":256631,"name":"Natália Buza","orcid":"0000-0002-0008-334X","position":1,"is_corresponding":false},{"id":316314,"name":"Pei Hui","orcid":null,"position":2,"is_corresponding":false},{"id":256632,"name":"Stefania Bellone","orcid":"0000-0001-5909-5292","position":3,"is_corresponding":false},{"id":315588,"name":"Burak Zeybek","orcid":"0000-0003-4146-8614","position":4,"is_corresponding":false},{"id":256635,"name":"Elena Ratner","orcid":"0000-0002-6277-6002","position":5,"is_corresponding":false},{"id":315598,"name":"Peter E. Schwartz","orcid":"0000-0002-0845-3624","position":6,"is_corresponding":false},{"id":315599,"name":"Giovanni Scambia","orcid":"0000-0002-9503-9041","position":7,"is_corresponding":false},{"id":256628,"name":"Alessandro D. Santin","orcid":"0000-0003-4724-9738","position":8,"is_corresponding":false},{"id":315590,"name":"Silvia Pelligra","orcid":"0000-0003-4415-1313","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":null,"created_at":"2026-07-18T23:12:54.309019Z","pmid":"32140533","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}